Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial

Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues

(2015) Andrea Antinori et al.   AIDS

Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

(2015) José R Arribas et al.   LANCET INFECTIOUS DISEASES

Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

(2015) José A Perez-Molina et al.   LANCET INFECTIOUS DISEASES

HIV protease inhibitors in gut barrier dysfunction and liver injury

(2014) Xudong Wu et al.   CURRENT OPINION IN PHARMACOLOGY

Antiretroviral Treatment of Adult HIV Infection

(2014) Huldrych F. Günthard et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial

(2014) Pedro Cahn et al.   LANCET INFECTIOUS DISEASES

The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load

(2012) JR Arribas et al.   HIV MEDICINE

Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study

(2011) M. A. Valantin et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA

(2011) N. Clumeck et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Factors Associated With Virological Failure in HIV-1–Infected Patients Receiving Darunavir/Ritonavir Monotherapy

(2011) Sidonie Lambert-Niclot et al.   JOURNAL OF INFECTIOUS DISEASES

Effectiveness of Protease Inhibitor Monotherapy versus Combination Antiretroviral Maintenance Therapy: A Meta-Analysis

(2011) Sandra Mathis et al.   PLoS One

Cost-Efficacy Analysis of the MONET Trial Using UK Antiretroviral Drug Prices

(2011) Brian Gazzard et al.   Applied Health Economics and Health Policy

HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review

(2009) Wouter FW Bierman et al.   AIDS

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml

(2009) Jose R Arribas et al.   AIDS